Fludarabine, cyclophosphamide and rituximab up to four courses as first line treatment for indolent non-hodgkin lymphomas

被引：0
|
作者：
Falantes, J. F. [1 ]
Ríos Herranz, E. [1 ]
Marin Niebla, A. [1 ]
Martino Galiana, M. L. [1 ]
Parody, R. [1 ]
Blas Orlando, J. M. [1 ]
机构：
[1] Hosp Univ Virgen Rocio, Seville, Spain
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1094
引用
收藏
页码：403 / 403
页数：1
相关论文
共 50 条
  • [31] Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas
    Ferrario, Andrea
    Pulsoni, Alessandro
    Olivero, Barbara
    Rossi, Giuseppe
    Vitolo, Umberto
    Tedeschi, Alessandra
    Merli, Francesco
    Rigacci, Luigi
    Stelitano, Caterina
    Goldaniga, Maria
    Mannina, Donato
    Musto, Pellegrino
    Rossi, Francesca
    Gamba, Enrica
    Baldini, Luca
    CANCER, 2012, 118 (16) : 3954 - 3961
  • [32] The addition of rituximab (R) to fludarabine and cyclophosphamide (FC) significantly improves outcomes in patients with chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (NHL)
    Tam, C
    Wolf, M
    Januszewicz, E
    Prince, H
    Westerman, D
    Lin, K
    Seymour, J
    ANNALS OF ONCOLOGY, 2005, 16 : 203 - 203
  • [33] Rituximab plus ICE as second-line treatment for relapsed and refractory aggressive non-Hodgkin lymphomas
    Panovska-Stavridis, I
    Georgievski, B
    Cevreska, L
    Stojanovski, Z
    Pivkova, A
    Krstevska-Balkanov, S
    Siljanovski, N
    BONE MARROW TRANSPLANTATION, 2005, 35 : S386 - S386
  • [34] Erythropoiesis in patients with aggressive and indolent non-Hodgkin's lymphomas
    Domnikova, NP
    Degtyareva, VV
    Nepomnyashchikh, LM
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2004, 138 (06) : 593 - 597
  • [35] Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma
    Barr, Paul M.
    Fu, Pingfu
    Lazarus, Hillard M.
    Horvath, Nancy
    Gerson, Stanton L.
    Koc, Omer N.
    Bahlis, Nizar J.
    Snell, Michael R.
    Dowlati, Afshin
    Cooper, Brenda W.
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 147 (01) : 89 - 96
  • [36] Erythropoiesis in patients with aggressive and indolent non-Hodgkin’s lymphomas
    N. P. Domnikova
    V. V. Degtyareva
    L. M. Nepomnyashchikh
    Bulletin of Experimental Biology and Medicine, 2004, 138
  • [37] Obinutuzumab for relapsed or refractory indolent non-Hodgkin's lymphomas
    Gabellier, Ludovic
    Cartron, Guillaume
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2016, 7 (02) : 85 - 93
  • [38] Current approaches to therapy for indolent non-Hodgkin's lymphomas
    Cheson, BC
    17TH INTERNATIONAL CANCER CONGRESS, VOL 1 AND 2, 1998, : 1357 - 1362
  • [39] Lenalidomide and rituximab for untreated indolent non-Hodgkin's lymphoma
    Fowler, N. H.
    McLaughlin, P.
    Kwak, L.
    Hagemeister, F.
    Fanale, M.
    Fayad, L.
    Pro, B.
    Samaniego, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [40] COST-EFFECTIVENESS ANALYSIS OF BENDAMUSTINE-RITUXIMAB TREATMENT COMPARED WITH FLUDARABINE-RITUXIMAB TREATMENT, IN PATIENTS WITH INDOLENT NON-HODGKIN'S LYMPHOMA IN COSTA RICA
    Desanvicente-Celis, Z.
    Obando, C. A.
    Chaves, M.
    Gonzalez, L.
    Muschett, D.
    VALUE IN HEALTH, 2014, 17 (03) : A85 - A85
12345